About Taxotere® (docetaxel) Injection Concentrate chemotherapy1-6
Taxotere® belongs to the taxane class of chemotherapy drugs. The
active ingredient in Taxotere® is derived from the needles of the
European yew tree, a renewable resource.
Discovery of Taxotere®
- In the early 1960s scientists at Research Triangle Institute (RTI) in North Carolina
observe anticancer activity in bark samples of the Pacific yew tree
- In 1971 RTI researchers identify paclitaxel as the active ingredient in Pacific
yew tree bark and publish structural data
- In 1986 scientists use a semi-synthetic conversion from precursors of paclitaxel
to develop docetaxel out of European yew needles
- In 1996 docetaxel, now called Taxotere®, is approved by the FDA
Metastatic breast cancer (MBC)
Taxotere® is indicated for the treatment of patients with locally
advanced or metastatic breast cancer after failure of prior chemotherapy.
Early-stage breast cancer (ESBC)
Taxotere® in combination with doxorubicin and cyclophosphamide is
indicated for the adjuvant treatment of patients with operable node-positive breast
Advanced NSCLC–Second line
Taxotere® as a single agent is indicated for the treatment of patients
with locally advanced or metastatic non-small cell lung cancer after failure of
prior platinum-based chemotherapy.
Metastatic Androgen Independent
Metastatic androgen independent prostate cancer (mAIPC)
Taxotere® in combination with prednisone is indicated for the treatment
of patients with androgen independent (hormone refractory) metastatic prostate cancer.
The following pages provide detailed information about Taxotere®: